Latest News
April 17, 2018
OrthoTrophix Will Present Data on Long-Term Clinical Benefit of TPX-100 in Mild to Severe Knee Osteoarthritis Patients at OARSI Annual Meeting 2018
November 7, 2017
OrthoTrophix Presents the Key Data of the TPX-100 Phase 2 Study as a Late Breaking Abstract at American College of Rheumatology Annual Meeting
December 15, 2016
Significant Improvements in Knee Function after TPX-100 Administration in a Double-Blind, Placebo-Controlled Phase 2 Study of Knee Osteoarthritis
Welcome
OrthoTrophix is an emerging biopharmaceutical company focused on the development and commercialization of revolutionary therapies for the treatment of diseases and conditions involving hard tissues such as bone, cartilage and teeth. The primary focus of OrthoTrophix is regeneration and repair of cartilage in the knee and other joints. The company’s leading therapeutic compound, TPX-100, has demonstrated sound safety profile as well as statistically significant and clinically meaningful improvements in function and other parameters of the knees in knee osteoarthritis subjects in Phase 2 clinical study. Prior to initiation of clinical studies, TPX-100 had demonstrated ability to repair articular (hyaline) cartilage in experimental defects in the knee joints of ambulatory large animal models.
